Trace amine associated receptor 1: predicted effects of single nucleotide variants on structure-function in geographically diverse populations

Hum Genomics. 2024 Jun 11;18(1):61. doi: 10.1186/s40246-024-00620-w.

Abstract

Trace Amine Associated Receptor 1 (TAAR1) is a novel pharmaceutical target under investigation for the treatment of several neuropsychiatric conditions. TAAR1 single nucleotide variants (SNV) have been found in patients with schizophrenia and metabolic disorders. However, the frequency of variants in geographically diverse populations and the functional effects of such variants are unknown. In this study, we aimed to characterise the distribution of TAAR1 SNVs in five different WHO regions using the Database of Genotypes and Phenotypes (dbGaP) and conducted a critical computational analysis using available TAAR1 structural data to identify SNVs affecting ligand binding and/or functional regions. Our analysis shows 19 orthosteric, 9 signalling and 16 micro-switch SNVs hypothesised to critically influence the agonist induced TAAR1 activation. These SNVs may non-proportionally influence populations from discrete regions and differentially influence the activity of TAAR1-targeting therapeutics in genetically and geographically diverse populations. Notably, our dataset presented with orthosteric SNVs D1033.32N (found only in the South-East Asian Region and Western Pacific Region) and T1945.42A (found only in South-East Asian Region), and 2 signalling SNVs (V1253.54A/T2526.36A, found in African Region and commonly, respectively), all of which have previously demonstrated to influence ligand induced functions of TAAR1. Furthermore, bioinformatics analysis using SIFT4G, MutationTaster 2, PROVEAN and MutationAssessor predicted all 16 micro-switch SNVs are damaging and may further influence the agonist activation of TAAR1, thereby possibly impacting upon clinical outcomes. Understanding the genetic basis of TAAR1 function and the impact of common mutations within clinical populations is important for the safe and effective utilisation of novel and existing pharmacotherapies.

Keywords: Agonists; Aminergic receptors; Amphetamines; Demographic; Genetic variants; Neuropsychiatric disorders; Neurotransmitters; Ralmitaront; Trace amines; Ulotaront.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Genotype
  • Humans
  • Ligands
  • Polymorphism, Single Nucleotide* / genetics
  • Receptors, G-Protein-Coupled* / genetics
  • Structure-Activity Relationship
  • Trace Amine-Associated Receptors

Substances

  • Trace amine-associated receptor 1
  • Receptors, G-Protein-Coupled
  • Ligands
  • Trace Amine-Associated Receptors